BACK TO EIGHTH GAVI BOARD MEETING
Eighth GAVI Board Meeting, Paris, 19-20 June 2002
7. The Vaccine Fund Draft
Strategic Plan and Emerging Policy Issues
here to download presentation [Powerpoint, 320 kb]
here to download paper [Word, 360 kb]
- The Board supported a longer-term perspective for
the Vaccine Fund, beyond the first five-year commitments. To meet
future needs, the Vaccine Fund needs to set ambitious fundraising
targets. While the environment is receptive to increased investments
in health, the Board noted that there is also great demand for
these new resources and that it will be important to be realistic.
- In the start-up phase, simplicity was a key concern.
The next phase may need to incorporate more flexibility to better
respond to diverse country situations.
- The introduction of new vaccines continues to be
a high priority for GAVI. In the next phase GAVI may consider
using Vaccine Fund resources to introduce available but under-used
vaccines such as Japanese encephalitis, MMR, rubella, IPV, and
other combination vaccines now being developed.
- While it cannot necessarily assumed that the Vaccine
Fund will purchase vaccines against meningococcus A, pneumococcus
and rotavirus once they are developed, their status as GAVI priority
vaccines indicate that this may indeed become a focus for resources.
Looking further into the future, purchase of vaccines against
AIDS, malaria and tuberculosis should be considered within the
context of The Vaccine Fund.
- A Board member raised concern that as the Vaccine
Fund builds its independent brand identity, a drift is occurring
between GAVI and the Vaccine Fund. Advocacy and public awareness
efforts on behalf of the Vaccine Fund must not undermine fundraising
for other immunization efforts.
2.1 Endorsed the need for ambitious, but reasonable
fundraising targets. Considering the substantial needs presented
by the Vaccine Fund, the Board recognized that the funding gap is
2.2 Requested that the Vaccine Fund develop a menu of
options, reflecting different levels of funding and program implementation,
for consideration by the GAVI Board in case the Vaccine Fund's fundraising
targets, and/or the countries' program targets, are not fully met.
2.3 Agreed that more Vaccine Fund resources should be
used support health infrastructure and capacity-building efforts,
and endorsed the proposal to give particular attention to the poorest
2.4 Requested the Vaccine Fund to work with the GAVI
Partners to assess the resourcing needs to reach the 80-80 milestone
(at least 80% DTP3 coverage in all districts in 80% of developing
countries by 2005). A proposal should then be presented to the GAVI
Board on how resources could be disbursed to help meet that target.
In this context, one option could be to fund operational research
that investigates the effectiveness of various approaches, including
their efficiency in improving health systems and outcomes.
2.5 Endorsed the clarification of current policy that
vaccine commitments to countries are antigen-based. The financial
implication of this clarification is estimated to be an additional
$625 million over the next 10 years. For example, if a country receives
five years' supply of DTP-hepB, it could apply for up to a five
years' supply of DTP-hepB-Hib - as long as it finds other funding
to cover the costs of the DTP-hepB portion.
2.6 Recommended further policy dialogue, especially
at the Partners' meeting, on issues related to the introduction
of new vaccines over the coming years, and also about the role and
potential of local production in reducing cost and securing supply.
The Developing Country Vaccine Manufacturers Network (DCVMN) could
play an important role in these discussions.
BACK TO EIGHTH GAVI BOARD MEETING